Fundraising Fox
Alphyn Biologics
Annapolis, US · Founded 2019 · 4 employees on LinkedIn · 2 known investors
Find your way into Alphyn Biologics
Sign up to find every way you can get introduced to Alphyn Biologics
- Your email: who you already know at Alphyn Biologics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Alphyn Biologics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Alphyn Biologics develops Multi-Target Therapeutics based on its Zabalafin (AB-101) platform to treat skin diseases, with a lead candidate, zabalafin hydrogel, a non-steroidal topical treatment for atopic dermatitis in children and adults that targets itch, inflammation, and Staph bacteria. The company operates in the biotech/dermatology drug development sector and has completed a Phase 2a clinical trial.
Founders & leadership
Alphyn Biologics was founded in 2019 by Jazmyne Mink.
Investors · 2
Reported raises · per SEC filings
Form D private placements$9.3M disclosed across 4 rounds · 2020–2024
▶$1.2MraisedMay 2024 · 17 investors · BiotechnologyRule 506(b)
▶$1.2MraisedMay 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven PentelnikExecutive Officer
- Jeffrey KossakDirector
- Gary PekoeExecutive Officer, Director
- Adel MikhailDirector
- Roger GriggsDirector
- Neal KollerExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.2M
- First sale
- May 2023
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedApr 2024 · 18 investors · BiotechnologyRule 506(b)
▶$5.2MraisedApr 2024 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neal KollerExecutive Officer, Director
- Gary PekoeExecutive Officer, Director
- Steven PentelnikDirector
- Roger GriggsDirector
- Jeffrey KossakDirector
- Adel MikhailDirector
- Tony ShipleyDirector
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$2.2MraisedMay 2022 · 7 investors · BiotechnologyRule 506(b)
▶$2.2MraisedMay 2022 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary PekoeExecutive Officer, Director
- Neal KollerExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $2.2M
- Minimum investment
- $10K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$800KraisedFeb 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$800KraisedFeb 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gary PekoeDirector
- Neal KollerExecutive Officer, Director
- Steven PentelnikExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $800K
- First sale
- Jan 2020
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Alpyn BeautyAlpyn Beauty makes skincare products that combine clinically proven active ingredients with wild-harvested mountain plants from Jackson Hole, Wyoming. Its vegan, cruelty-free line includes serums, cleansers, and creams sold direct to consumers, with a portion of sales donated to national park restoration.
Alnylam PharmaceuticalsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Avalyn Pharma IncAvalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies. The company operates in the biotech and respiratory drug development space.
Companies working in the same space as Alphyn Biologics.
Frequently asked questions
- What does Alphyn Biologics do?
- Alphyn Biologics develops Multi-Target Therapeutics based on its Zabalafin (AB-101) platform to treat skin diseases, with a lead candidate, zabalafin hydrogel, a non-steroidal topical treatment for atopic dermatitis in children and adults that targets itch, inflammation, and Staph bacteria. The company operates in the biotech/dermatology drug development sector and has completed a Phase 2a clinical trial.
- Who founded Alphyn Biologics?
- Alphyn Biologics was founded by Jazmyne Mink in 2019.
- Who are Alphyn Biologics's investors?
- Alphyn Biologics's investors include Angel Physicians Fund, QCA First.
- How much funding has Alphyn Biologics raised?
- Alphyn Biologics has disclosed $9.3M raised across 4 rounds.
- Where is Alphyn Biologics headquartered?
- Alphyn Biologics is headquartered in Annapolis, US.